BIOLASE Technology, Inc. (Nasdaq: BLTI) shares leaped 19.1% to $3.31, after reporting quarterly net revenue of $12.1 million, up 105% from $5.9 million in the same quarter for 2010. Volume for the stock was more than 717,000, already surpassing a daily average of around 636,000.
A news release issued August 10 also noted that Q2 GAAP loss was $753,000, or $0.03 per share, with Q2 Non-GAAP profits around $6,000, or $0.00 per Share. This was the third consecutive quarter of Non-GAAP profit, first time since the second quarter of 2004.
The release also said the percentage of net revenue in this year’s second quarter from the U.S. and international markets totaled approximately 71% and 29%, respectively, as compared to approximately 60% and 40% of net revenue in the prior-year comparable period.
Federico Pignatelli, Chairman and CEO, was quoted in the same release as saying, “The rate of revenue growth and operational progress at the Company continued to accelerate in the second quarter and our momentum going into the second half of the year is strong. Sales activities across our laser product platforms remained very active — especially in the case of the Waterlase iPlus, which we believe will become the most successful all-tissue dental laser in history. In addition, we are now taking orders and will soon be shipping the first units from our new BIOLASE DaVinci Imaging™ product line.”
BIOLASE Technology, Inc., the world’s leading dental laser company, based in Irvine, California, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine.